Olanzapina Aurovitas (Olanzapine)

Olanzapine, the active ingredient in Olanzapina Aurovitas, is an atypical antipsychotic presented as a tablet for oral use. It is employed in the management of schizophrenia and bipolar disorder in adult patients. GNH USA supplies Olanzapina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Olanzapina Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapina Aurovitas is an atypical antipsychotic that modulates neurotransmission in psychotic and mood disorders.

- Schizophrenia: helps control delusions, hallucinations and thought disorder. - Bipolar I disorder (manic episodes): reduces manic symptoms and stabilises mood. - Maintenance therapy for schizophrenia or bipolar disorder: helps prevent relapse and sustain symptom control.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or feeling of being slowed. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility. - Elevated triglycerides: changes in lipid metabolism. - Orthostatic hypotension: drop in blood pressure when standing.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: high fever, muscle rigidity, autonomic instability. - Tardive dyskinesia: involuntary, repetitive movements, often of the face. - Hyperglycaemia: significant rise in blood glucose levels. - Seizures: risk of convulsive episodes. - Agranulocytosis: marked reduction in white‑blood cell count. - Severe allergic reactions: anaphylaxis or angio‑angry   

Olanzapine should be used ​  

-   \\  \\  \